RudaCure Pursues Global Partnering for RCI001/RCI002 and Expanded Gene Therapy Co-Development at 2025 BIO-USA
RudaCure Inc. announced its participation in the **国际生物技术大会 (BIO-USA)** 2025 held in the 美国, where it will conduct overseas licensing and 联合开发 partnering meetings for its major 管线s: RCI001 (干眼症治疗药) and **RCI002 (TRPV1-targeted 镇痛)**.
At the event, RudaCure will meet with world-renowned 眼科 制药公司 including Santen of 日本 and Thea of 法国 to share the development status and domestic/international 临床试验 progress of RCI001, and conduct in-depth discussions on 联合开发 and 全球市场 entry possibilities.
In the field of 镇痛 development, the company plans to present the research results and commercial potential of RCI002 to major global 制药公司. RCI002, a 创新药物候选物 that simultaneously targets TRPV1 and MOR (Mu阿片受体), has demonstrated potent 镇痛效果 at very low doses in 临床前研究, earning attention as a 非麻醉性镇痛药 that overcomes the 成瘾性 and 耐药性 issues of opioid-based treatments. Various companies have shown strong interest, and this BIO-USA provides an important opportunity to explore specific 对外许可 and 联合开发 models.
RudaCure is currently also pursuing 联合开发 of a 基因治疗-based 疼痛治疗药 for 兽用 use, leveraging its proprietary 离子通道-targeted peptide technology combined with AAV (Adeno-Associated Virus) vectors. This project, recently selected for the Ministry of Agriculture's Agri-Food Venture Development Program, is expected to serve as a platform technology applicable to both human and 兽药s, and discussions with multiple overseas partners are expected to accelerate during BIO-USA.
CEO Yongho Kim stated, "BIO-USA 2025 will be a pivotal milestone for RudaCure's 全球拓展. Based on the clinical outcomes of RCI001 and the innovative mechanism of RCI002, we will proactively advance partnerships with global 制药公司 and establish ourselves as a new drug developer with global presence."
